ep395
Small moleculeexperimental
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 5, 2021 (NCT04819854)
Timeline
Indications
Mechanism of action
- 50S ribosomal protein L2INHIBITOR
rplB inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06677918 | Phase 1 | Jan 1, 2025 | EpiEndo Pharmaceuticals, FGK Clinical Research GmbH |
| NCT06118684 | Phase 1 | Oct 23, 2023 | Clinical Trial Consultants AB, EpiEndo Pharmaceuticals |
| NCT05572333 | Phase 2 | Nov 22, 2022 | EpiEndo Pharmaceuticals, FGK Clinical Research GmbH |
| NCT05516316 | Phase 1 | Oct 11, 2022 | EpiEndo Pharmaceuticals, FGK Clinical Research GmbH, University of California, Irvine |
| NCT04819854 | Phase 1 | Apr 5, 2021 | EpiEndo Pharmaceuticals, Medicines Evaluation Unit Ltd |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| EpiEndo Pharmaceuticals | For profit | 5 | 5 | 2 | 2021 |
| FGK Clinical Research GmbH | For profit | 3 | 0 | 2 | 2022 |
| Clinical Trial Consultants AB | For profit | 1 | 0 | 1 | 2023 |
| Medicines Evaluation Unit Ltd | For profit | 1 | 0 | 1 | 2021 |
| University of California, Irvine | Academic/Hospital | 1 | 0 | 1 | 2022 |
5 organizations
Page 1 / 1